Advertisement

Pharmacotherapy of Adolescent Problems

  • Magda Campbell
  • Richard Perry
  • Richard P. Malone

Abstract

Research and clinical trials in psychopharmacology of autism mainly involve young autistic children (for review, see Campbell, 1987). The occasional adolescent or young adult in some studies represents only part of a patient sample with a very wide age range. This is particularly true for most studies of fenfluramine (Ritvo et al., 1986; for review see Campbell, 1987, 1988). It is not clear why these adolescents or young adults were selected to participate in these clinical trials, whether their behavioral symptoms differed from those of young patients. Certainly, it is not known whether autistic adolescents respond in the same way to pharmacotherapy as younger children do. It should be noted that a certain number of autistic persons develop seizure disorder around puberty which deserves careful consideration when prescribing a psychoactive agent (Gualtieri et al., 1987; Tarjan et al., 1957). Side effects of antiseizure drugs are discussed by Gualtieri et al. (1987).

Keywords

Adolescent Psychiatry Autistic Child Pervasive Developmental Disorder Infantile Autism Target Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler, L., Angrist, B., Peselow, E., Corwin, J., & Rotroen, J. (1985). Efficacy of propranolol in neuroleptic-induced akathisia. Journal of Clinical Psychopharmacology, 5, 164–166.PubMedCrossRefGoogle Scholar
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (DSM-171). (3ml ed.)1980. Washington DC: Author.Google Scholar
  3. Anderson, J. C., Williams, S., McGee, R., & Silva, P. A. (1987). DSM-III disorders in preadolescent children. Archives of General Psychiatry, 44,69–76.PubMedCrossRefGoogle Scholar
  4. Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19,227-239.PubMedCrossRefGoogle Scholar
  5. Anderson, L T., Campbell, M., Grega, D. M., Perry, R, Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141,1195-1202.PubMedGoogle Scholar
  6. Barrett, R P., Feinstein, C., & Hole, W. T. (1989). Effects of naltrexone on self-injury: A double-blind, placebo-controlled analysis. American Journal of Mental Retardation, 93, 644–651.PubMedGoogle Scholar
  7. Beckwith, B. E., Couk, D. I., & Schumacher, K. (1986). Failure of naloxone to reduce self-injurious behavior in two developmentally disabled females. Applied Research in Mental Retardation, 7, 183–188.CrossRefGoogle Scholar
  8. Bernstein, G. A., Hughes, J. R, Mitchell, J. E., & Thompson, T. (1987). Effects of Narcotic Antagonists on Self-injurious Behavior: A Single Case Study. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 886–889.PubMedGoogle Scholar
  9. Campbell, M. (1987). Drug treatment of infantile autism: The past decade. In H. Y. Meltzer (Ed.), Psychopharmacology:: The Third Generation of Progress (pp 1225–1231 ). New York: Raven Press.Google Scholar
  10. Campbell, M. (1988). Fenfluramine treatment of autism. Annotation. Journal of Child Psychology and Psychiatry, 29,1–10.PubMedCrossRefGoogle Scholar
  11. Campbell, M., & Schopler, E. (Co-chairmen). (1989). Pervasive Developmental Disorders. In T. Byran Karasu (Chairman), Psychiatric Treatment Manual I (PTM-1), APA Task Force on Treatment of Psychiatric Disorders Washington, D C: American Psychiatric Press, Inc.Google Scholar
  12. Campbell, M., Fish, B., Korein, J., Shapiro, T., Collins, P., & Koh, C. (1972). Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. Journal of Autism and Childhood Schizophrenia, 2, 234–263.PubMedCrossRefGoogle Scholar
  13. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., & Sachar, E. J. (1978). A comparison of haloperidol, behavior therapy and their interaction in autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 17, 640–655.CrossRefGoogle Scholar
  14. Campbell, M., Grega, D. M., Green, W. H., & Bennet, W. G. (1983). Neuroleptic- induced dysldnesias in children. Clinical Neuropharmacology, 6, 207–222.PubMedCrossRefGoogle Scholar
  15. Campbell, M., Adams, P., Perry, R, Spencer, E. K., & Overall, J. E. (1988a). Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharmacological Bulletin, 24, 251–255.Google Scholar
  16. Campbell, M., Adams, P., Small, A. M., Curren, E. L., Overall, J. E., Anderson, L. T., Lynch, N., & Perry, R (1988b). Efficacy and safety of fenfluramine in autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 434–439.PubMedCrossRefGoogle Scholar
  17. Campbell, M., Overall, J. E., Small, A. M., Sokol, M. S., Spencer, E. K., Adams, P., Foltz, R. L., Monti, K. M., Perry, R., Nobler, M., & Roberts, E. (1989). Naltrexone in autistic children: An acute open dose range tolerance trial. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 200–206.PubMedCrossRefGoogle Scholar
  18. Campbell, M., Perry, R., & Green, W. H. (1984a). The use of lithium in children and adolescents. Psychosomatics, 25,95-106.PubMedCrossRefGoogle Scholar
  19. Campbell, M., Small, A. M., Green, W. H., Jennings, S. J., Perry, R, Bennett, W. G., & Anderson, L. (1984b). Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Archives of General Psychiatry, 41, 650–656.PubMedCrossRefGoogle Scholar
  20. Casey, D. E. (1987). Tardive dyskinesia. In H. Y. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress (pp 1411–1419 ). New York: Raven Press.Google Scholar
  21. Cohen, D. J., & Donellan, A. M. (Eds.) (1987). Handbook of Autism and Developmental Disorders. New York: Wiley & Sons.Google Scholar
  22. Cohen, I. L., Campbell, M., Posner, D., Small, A. M., Triebel, D., & Anderson, L. T. (1980). Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. Journal of the American Academy of Child Psychiatry, 19,665-677.PubMedCrossRefGoogle Scholar
  23. Craft, M., Ismail, I. A., Krishnamurti, D., Mathews, J., Regan, A., Seth, R. V., & North, P. M. (1987). Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. British Journal of Psychiatry, 150, 685–689.PubMedCrossRefGoogle Scholar
  24. DeMyer, M. K., Hintgen, J. N., & Jackson, R K. (1981). Infantile autism reviewed. A decade of research. Schizophrenia Bulletin, 7, 388–451.PubMedCrossRefGoogle Scholar
  25. Deutsch, S. I. (1986). Rationale for the Administration of Opiate Antagonists in Treating Infantile Autism. American Journal of Mental Deficiency, 90, 631–635.PubMedGoogle Scholar
  26. Dostal, T. (1972). Antiaggressive effect of lithium salts in mentally retarded adolescents. In A. L. Annell (Ed.), Depressive States in Childhood and Adolescence (pp 491–498 ). Stockholm: Almgvist & Wiksell.Google Scholar
  27. Ekman, G., Miranda-Linne, F., Gillberg, C., Garle, M., & Wetterberg, L. (1989). Fenfluramine treatment of 20 autistic children. Journal of Autism and Developmental Disorders,(in press).Google Scholar
  28. Elliott, F. A. (1977). Propranolol for the control of belligerent behavior following acute brain damage. Annals of Neurology, 1, 489–491.PubMedCrossRefGoogle Scholar
  29. Elliott, R. L. (1986). Lithium treatment and cognitive changes in two mentally retarded patients. Journal of Nervous and Mental Disease, 174, 689–692.PubMedCrossRefGoogle Scholar
  30. Evans, R. W., Clay, T. H., & Gualtieri, C. T. (1987). Carbamazepine in pediatric psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 2–8.PubMedCrossRefGoogle Scholar
  31. Faim, M. E., Smith, R. C., Davis, J. M., & Domino, E. F. (Eds.) (1980). Tardive Dyskinesia: Research and Treatment. Jamaica, New York: Spectrum Publication, Inc.Google Scholar
  32. Farber, J. M. (1987). Psychopharmacology of self-injurious behavior in the mentally retarded. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 296–302.PubMedCrossRefGoogle Scholar
  33. Fish, B. (1970). Psychopharmacologic responses of chronic schizophrenic adults as predictors of responses in young schizophrenic children. Psychopharmacological Bulletin, 6, 12–15.Google Scholar
  34. Gillberg, C., & Schaumann, H. (1981). Infantile autism and puberty. Journal of Autism and Developmental Disorders, 11, 365–371.PubMedCrossRefGoogle Scholar
  35. Gualtieri, T., Evans, R W., & Patterson, D. R. (1987). The medical treatment of autistic people. In E. Schopler & G. B. Mesibov (Eds.), Neurobiological Issues in Autism (pp 373–388 ). New York: Plenum Press.Google Scholar
  36. Gualtieri, C. T., Quade, D., Hicks, R. E., Mayo, J. P., & Schroeder, S. R (1984). Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. American Journal of Psychiatry, 141, 20–23.PubMedGoogle Scholar
  37. Hawkins, D. & Pauling, L. (Eds.) (1973). Orthomolecular Psychiatry. San Fransisco: W. H. Freeman.Google Scholar
  38. Herman, B. H., Hammock, M. K., Arthur-Smith, A., Egan, J., Chatoor, I., Werner, A., & Zelnik, N. (1987). Naltrexone decreases self-injurious behavior. Annals of Neurology, 22, 550–552.PubMedCrossRefGoogle Scholar
  39. Herman, B. H., Hammock, M. K., Arthur-Smith, A., Egan, J., Chatoor, I., Zelnik, N, Appelgate, K., Boeckx, R L. (1986). Effects of naltrexone in autism: Correlation with plasma opioid concentrations: American Academy of Child and Adolescent Psychiatry, Scientific Proceedings for the Annual Meeting, (2), 11–12.Google Scholar
  40. Kerbeshian, J., Burd, L., & Fisher, W. (1987). Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. Journal of Clinical Psychopharmacology, 7, 401–405.PubMedGoogle Scholar
  41. Langee, H. R (1989). A retrospective study of mentally retarded patients with behavioral disorders who were treated with carbamazepine. American Journal of Mental Retardation, 93, 640–643.PubMedGoogle Scholar
  42. Leboyer, M., Bouvard, M. P., & Dugas, M. (1988). Effects of naltrexone on infantile autism. Lance4 March 26, p 715.CrossRefGoogle Scholar
  43. Leventhal, B. L. (1985). Fenfluramine administration to autistic children: Effects on behavior and biogenic amines. Paper presented at the 25th NCDEU Annual (Anniversary) Meeting, Key Biscayne, Florida, May 1–4.Google Scholar
  44. Lipman, R. S. (1986). Overview of research in psychopharmacological treatment of the mentally ill/mentally retarded. Psychopharmacology Bulletin, 22, 1046–1054.PubMedGoogle Scholar
  45. Marcus, L. M., & Schopler, E. (1987). Working with families: A developmental perspective. In D. J. Cohen & A. M. Donnellan (Eds.), Handbook of Autism and Pervasive Developmental Disorders (pp 499–512 ). New York: Wiley & Sons.Google Scholar
  46. Mattes, J. A. (1986). Psychopharmacology of temper outbursts. A review. Journal of Nervous and Mental Disease, 174, 464–470.PubMedCrossRefGoogle Scholar
  47. Naruse, H., Nagahata, M., Nakane, Y., Shirahashi, K., Takesada, M., & Yamazaki, K. (1982). A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavior disorders, using cross-over design. Acta Paedopsychiatdca, 48,173-184.Google Scholar
  48. Pauling, L. (1968). Orthomolecular psychiatry, Science, 160, 265–271.PubMedCrossRefGoogle Scholar
  49. Payton, J. B. (1987). Depression in non-retarded autistics. Abstract NR-74A, Scientific Proceedings of the Annual Meeting. Vol. III, American Academy of Child and Adolescent Psychiatry, Washington, D. C., October 21–25, p 54.Google Scholar
  50. Perry, R., Campbell, M., Grega, D. M., & Anderson, L. (1984). Saliva lithium levels in children: Their use in monitoring serum lithium levels and lithium side effects. Journal of Clinical Psychopharmacology, 4,199-202.PubMedGoogle Scholar
  51. Perry, R., Campbell, M., Adams, P., Lynch, N., Spencer, E. K., Curren, E. L., & Overall, J. E. (1989a). Long-term efficacy of haloperidol in autistic children: Continuous vs. discontiuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 87–92.PubMedCrossRefGoogle Scholar
  52. Perry, R., Nobler, M. S., & Campbell, M. (1989b). Case Report: Tourette-like symptoms associated with chronic neuroleptic therapy in an autistic child. Journal of the American Academy of Child and Adolescent Psychiatry, 28,93-96.PubMedCrossRefGoogle Scholar
  53. Polakoff, S. A., Sorgi, P. J., & Ratey, J. J. (1986). The Treatment of Impulsive and Aggressive Behavior with Nadolol. Journal of Clinical Psychopharmacology, 6, 125–126.PubMedCrossRefGoogle Scholar
  54. Post, R M. (1987). Mechanisms of action of carbamazepine and related anticonvulsants in affective illness. In H. Y. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress (pp 567–576 ). New York: Raven Press.Google Scholar
  55. Post, R M. (1988). Time course of clinical effects of carbamazepine: implications of mechanisms of action. Journal of Clinical Psychiatry, 49, suppl., 35–46.PubMedGoogle Scholar
  56. Raiten, D. J. (1987). Nutrition and developmental disabilities. In E. Schopler & G. B. Mesibov (Eds.), Neurobiological Issues in Autism (pp 325–338 ). New York: Plenum Press.Google Scholar
  57. Raiten, D. J., & Massaro, T. F. (1987). Nutrition and developmental disabilities: An examination of the orthomolecular hypothesis. In D. J. Cohen & A. M. Donnellan (Eds.), Handbook of Autism and Pervasive Developmental Disorders (pp 566–583 ). New York: Wiley & Sons.Google Scholar
  58. Ratey, J. J., Bemporad, J., Sorgi, P., Bick, P., Polakoff, S., O’Driscoll, G., & Mikkelsen, E. (1987a). Brief report: Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. Journal of Autism and Developmental Disorders, 17, 439–446.PubMedCrossRefGoogle Scholar
  59. Ratey, J. J., Mikkelsen, E., Sorgi, P., Zuckerman, S., Polakoff, S., Bemporad, J., Bick, P., & Kadish, W. (1987b). Autism: The Treatment of Aggressive Behaviors. Journal of Clinical Psychophannacology, 7, 35–41.Google Scholar
  60. Ratey, J. J., Mikkelsen, E., Smith, G. B., Upadhyaya, A., Zuckerman, H. S., Martell, D., Sorgi, P., Polakoff, S., & Bemporad, J. (1986). Beta-blockers in the severely and profoundly mentally retarded. Journal of Clinical Psychopharmacology, 6, 103–107.PubMedCrossRefGoogle Scholar
  61. Reisberg, B., & Gershon, S. (1979). Side effects associated with lithium therapy. Archives of General Psychiatry, 36, 879–887.PubMedCrossRefGoogle Scholar
  62. Remschmidt, H. (1976). The psychotropic effect of carbamazepine in non-epileptic patients, with particular reference to problems posed by clinical studies in children with behavioral disorders. In W. Birkmayer (Ed.), Epileptic Seizures–Behaviour–Pain (pp 253–258 ). Bem: Hans Huber.Google Scholar
  63. Richardson, J. S., & Zaleski, W. A. (1983). Naloxone and self-mutilation. Biological Psychiatry, 18,99-101.PubMedGoogle Scholar
  64. Rimland, B. (1987). Megavitamin B6 and magnesium in the treatment of autistic children and adults. In E. Schopler & G. B. Mesibov (Eds.), Neurological Issues in Autism (pp 389–405 ). New York: Plenum Press.Google Scholar
  65. Ritvo, E. R, Freeman, B. J., Geller, E., & Yuwiler, A. (1983). Effects of fenfluramine on 14 outpatients with the syndrome of autism. Journal of the American Academy of Child Psychiatry, 22, 549–558.PubMedCrossRefGoogle Scholar
  66. Ritvo, E. R, Yuwiler, A., Geller, E., Schroth, P., Yokota, A., Mason-Brothers, A., August, G. J., Klykylo, W., Leventhal, B., Lewis, K., Piggott, L., Realmuto, G., Stubbs, E. G., & Umansky, R. (1986). Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacological Bulletin, 22, 133–140.Google Scholar
  67. Sandman, C A, Datta, P. C., Barron, J., Koehler, F. K., Williams, C., & Swanson, J. M. (1983). Naloxone attenuates self-abusive behavior in developmentally disabled clients. Applied Research in Mental Retardation, 4,5-11.PubMedCrossRefGoogle Scholar
  68. Schopler, E., & Mesibov, G. B. (Eds.) (1983). Autism in Adolescence and Adults. New York: Plenum.Google Scholar
  69. Shopsin, B., Gershon, S., & Pinckney, L. (1969). The secretion of lithium in human mixed saliva: Effects of ingested lithium on electrolyte distribution in saliva and serum. International Pharmacopsychiatry, 2, 148–169.Google Scholar
  70. Silver, J. M., Yudofsky, S. C., Kogan, M., & Katz, B. L. (1986). Elevation of thioridazine plasma levels by propranolol. American Journal of Psychiatry, 143, 1290–1292.PubMedGoogle Scholar
  71. Spencer, E. K., & Campbell, M. (1989). Aggressiveness directed against self and others: Psychopharmacologic intervention. In S. L. Harris & J. S. Handleman (Eds.), Life Threatening Behavior: Aversive vs. Nonaversive Interventions (in press).Google Scholar
  72. Szymanski, L., Kedesdy, J., Sulkes, S., Cutler, A., & Stevens-Our, P. (1987). Naltrexone in treatment of self injurious behavior: a clinical study. Research in Developmental Disabilities, 8, 179–190.PubMedCrossRefGoogle Scholar
  73. Tarjan, G., Lowery, V. E., & Wright, S. W. (1957). The use of chlorpromazine in 278 mentally deficient patients. American Medical Association Journal of Disturbed Children, 94, 294–300.Google Scholar
  74. Tyrer, S. P., Walsh, A., Edwards, D. E., Berney, T. P., & Stephens, D. A. (1984). Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 8, 751–755.CrossRefGoogle Scholar
  75. Vitiello, B., Behar, D., Malone, R., Delaney, M. A., Ryan, P. J., & Simpson, G. M. (1988). Pharmacokinetics of lithium carbonate in children. Journal of Clinical Psychophannacology, 8, 355–359.Google Scholar
  76. Walters, A. S., Barrett, R. P., Feinstein, C., Mercurio, A., & Hole, W. (1989). The treatment of self-injury and social withdrawal in autism with naltrexone. Paper presented at the Eastern Psychological Association Meeting, Boston, MA, March 1989.Google Scholar
  77. Weischer, M. L. (1969). Über die antiaggressive Wirkung von Lithium. Psychopharmacologia, 15,245-254.CrossRefGoogle Scholar
  78. Weller, E. B., Weller, R. A., Fristad, M. A., Cantwell, M., & Tucker, S. (1987). Saliva lithium monitoring in prepubertal children. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 173–175.PubMedCrossRefGoogle Scholar
  79. White, T. J. R., & Aman, M. G. (1985). Pimozide treatment in disruptive severely retarded patients. Australian and New Zealand Journal of Psychiatry, 19, 92–94.PubMedCrossRefGoogle Scholar
  80. Williams, D. T., Mehl, R., Yudofsky, S., Adams, D., & Roseman, B. (1982). The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Journal of the American Academy of Child Psychiatry, 21, 129–135.PubMedCrossRefGoogle Scholar
  81. Wing, L., & Attwood, A. (1987). Syndromes of autism and atypical development. In D. J. Cohen & A. M. Donnellan (Eds.), Handbook of Autism and Developmental Disorders (pp 3–19 ). New York: Wiley & Sons.Google Scholar
  82. Yudofsky, S., Williams, D., & Gorman, J. (1981). Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndrome. American Journal of Psychiatry, 138, 218–230.Google Scholar
  83. Ziring, P. R., & Teitelbaum, L. (1980). Affiliation with a university department of psychiatry: Impact on the use of psychoactive medication in a large public residential facility for mentally retarded persons. Paper presented at the conference on use of medications in controlling the behavior of the mentally retarded. September 22–24, University of Minnesota, Minneapolis, Minnesota.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Magda Campbell
  • Richard Perry
  • Richard P. Malone

There are no affiliations available

Personalised recommendations